HER2 Support Group Forums - Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Surviv

HER2 Support Group Forums (https://her2support.org/vbulletin/index.php)

- Breast Cancer Newsfeed (https://her2support.org/vbulletin/forumdisplay.php?f=52)

- - Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Surviv (https://her2support.org/vbulletin/showthread.php?t=41660)

News	10-31-2009 04:11 AM

Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Surviv

Eisai Inc. announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

More...

All times are GMT -7. The time now is 10:52 PM.